Most Read Articles
3 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 4 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, Yesterday

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

Aflibercept provides effective alternative to intravitreal ranibizumab

10 Jun 2020

Aflibercept induces a favourable short-term response among pachychoroid neovasculopathy (PNV) patients who do not respond to intravitreal ranibizumab, a recent study has found.

Fourteen eyes of 14 patients (mean age, 64.1±7.5 years; 50 percent male) with PNV were included in the study. Only those with inadequate responses to at least three injections of ranibizumab―and switched to aflibercept―were eligible. The primary outcome measure was the percentage of eyes with dry macula 4 weeks after the last aflibercept injection.

At baseline, all eyes had subretinal fluid, which remained throughout every visit while participants were under ranibizumab treatment.

However, after the third aflibercept injection, more than half of the eyes (57.1 percent; n=8) achieved dry macula status without serous pigment epithelium detachment or subretinal or intraretinal fluid. It took an average of 1.7±0.9 aflibercept injections before complete fluid resolution in these eyes.

One eye achieved dry macula status after the first aflibercept injections, though developed recurrent subretinal fluid after the second and third administrations.

In terms of the secondary outcomes, subretinal fluid thickness decreased significantly after three aflibercept injections (102±48 to 39±62 µm; p=0.0009). A similar nominal decrease was observed during the ranibizumab treatment period, though statistical significance was not achieved (p=0.084).

Aflibercept was also safe and did not lead to any serious adverse events, such as retinal detachment and macular haemorrhage, during the study period.

Editor's Recommendations
Most Read Articles
3 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 4 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, Yesterday

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.